Product ID: SQMIG35I2199
Report ID:
SQMIG35I2199 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
62 |
Figures:
77
In August 2023 Sandoz, one of a global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko, developed by Polpharma Biologics. Tyruko is approved to treat all indications covered by the reference medicine and is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis (MS).
In Jan 2023 FDA has approved ublituximab-xiiy (Briumvi; TG Therapeutics Inc) for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In December 2022 U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35I2199